Replies to post #177216 on Biotech Values

[genisi]

I really cannot predict but I think investors are already expecting HIV sales to flatten as Viread goes off patent and are also very excited with HCV sales, so perhaps not going to punish GILD's share strongly (as it should be) if TAF is as good as Viread but not statsig better.